‘DURVIT’: a phase-I trial of single low-dose durvalumab (Medi4736) IntraTumourally injected in cervical cancer: safety, toxicity and effect on the primary tumour- and lymph node microenvironment
Journal article published in 2018 by
J. Rotman,
C. H. Mom 
,
E. S. Jordanova,
T. D. de Gruijl,
G. G. Kenter
,
E. S. Jordanova,
T. D. de Gruijl,
G. G. Kenter
This paper is made freely available by the publisher.
Full text: Download
Data provided by 